Paradromics Inc.
Paradromics Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Paradromics Inc..
Paradromics Inc. is a company.
Key people at Paradromics Inc..
Key people at Paradromics Inc..
Paradromics Inc. develops the Connexus® Direct Data Interface (DDI), a high-data-rate, fully implantable brain-computer interface (BCI) platform that records neural signals from individual neurons for long-term daily use.[1][2][3][4] It primarily serves individuals with severe motor impairments, such as paralysis, by translating brain signals into synthesized speech, text, and cursor control to restore communication and computer independence, with plans to expand to conditions like chronic pain, addiction, and depression.[1][2][4][5] The company has raised approximately $140M to date, including early DARPA and NIH funding, and achieved key milestones like multiple FDA Breakthrough Device Designations and IDE approval in November 2025 for its Connect-One clinical study.[1][2][3][5]
Founded in 2015 by CEO Matt Angle, Paradromics originated from his Stanford University research on translating lab-based neural recording into a fully implantable, wireless commercial medical device.[2][3] Early traction came swiftly: within two years, it secured $15M in NIH SBIR and DARPA contracts, enabling proof-of-concept development and a 2018 venture raise.[2][3] Pivotal shifts included a 2019 pivot to product focus under COO James Burrows, relocation to Austin, Texas, pre-clinical demos of record channel counts by 2022, and key hires like CSO Vikash Gilja in 2023, plus an Oakland office for AI.[3] By 2023, a $33M round led by Prime Movers Lab fueled progress toward FDA milestones.[2][3]
Paradromics rides the exploding neurotechnology wave, where high-resolution BCIs address unmet needs in paralysis (affecting millions) and expand to mental health via AI-driven neural decoding.[1][2][4] Timing aligns with FDA's prioritization of transformative devices—evidenced by Breakthrough status—and surging investor interest, as seen in its $140M funding amid competitors like Neuralink.[1][2] Market forces like aging populations, rising neurological disorders, and AI advancements favor its scalable platform, positioning it to influence human-AI symbiosis, prosthetics, and immersive tech while democratizing brain health beyond labs.[3][4][5]
Paradromics is primed for Q1 2026 clinical launch of the Connect-One study, testing Connexus safety and speech restoration—the first IDE for fully implantable BCI speech—potentially unlocking pivotal patient data and partnerships.[3][5] Trends like AI neural decoding and scalable implants will propel expansion to motor control, pain, and beyond, challenging incumbents with superior bandwidth. Its influence could evolve from niche medical device to ecosystem enabler for neural-tech integration, amplifying impact as regulatory wins compound and funding scales, fulfilling its promise of boundless brain-health applications.[1][4]
